Latest: FDA Approves New Biosimilar for Oncology Treatment
Neurology

Amylyx Discontinues AMX0035 Program in Supranuclear Palsy Following Disappointing Phase 2b Data

by Neurology Live
0 Comments
0 Mins
Amylyx Pharmaceuticals discontinued its AMX0035 program for progressive supranuclear palsy after a phase 2b trial failed to show efficacy.
Tags:
Neurology Live
Author

Neurology Live

Previous Post
Davina McCall Opens Up: Terrified of Dying Before Brain Surgery
Next Post
Pauly Shore Reveals Pancreas Tumor Surgery and Tough Recovery
📢

Advertisement

300x250 Banner

Recent Content

COPD Biologics: Early Treatment Insights

Pulmonology • 2 hours ago

Antihypertensive Medication Guidelines

Cardiology • 4 hours ago

Juvenile Arthritis Care Transition

Rheumatology • 6 hours ago